How to Invest in Biotech Stocks: A Beginner's Guide

Most companies are valued on what they earn. A small biotech usually earns nothing. It is valued on a guess: will its drug work, will the FDA approve it, and will the company still have money when that happens?

That is why one press release can move a biotech stock 50% in a morning. A trial result or an FDA decision changes the guess overnight. Investors call these moments catalysts, and they are the heartbeat of biotech investing.

Here is what that looks like in numbers. We looked at 22,234 past biotech stock-months from June 2022 to March 2026, using only what was known on each date. Over the following six months the median stock fell 3.5%. About 13 in 100 rose 50% or more. About 24 in 100 fell 30% or more. Big winners exist, but the average biotech drifts down, and the drops are more common than the jumps.

1. The next catalyst. What could move the stock in the next six months? A Phase 3 readout, a PDUFA date, an advisory committee meeting. If there is nothing on the calendar, you are waiting for the market's mood, not for news.
2. The cash. How many months of spending does the company have in the bank? A company that runs out before its catalyst will sell new shares first, and that usually hurts the price. More in cash runway and dilution.
3. The science. Which phase is the lead drug in, and how was the trial designed? A randomized, double-blind Phase 3 is a much stronger test than an open-label Phase 1. See clinical trial phases explained.
4. Who owns it. Are specialist biotech hedge funds in the stock? Are insiders buying with their own money? Neither is a guarantee, but both are worth knowing. See hedge funds and insider buying.
5. The price. Is the stock already at its high, priced for good news? Or far below it, with the bad news already in?

None of these on its own picks winners. Together they tell you what you are actually betting on.

If you want biotech exposure without single-stock risk, a biotech ETF spreads your money across many companies. The two best known are XBI, which gives small and mid-size companies a similar weight, and IBB, which leans toward the large, profitable names. A failed trial at one company barely shows up in either fund.

Picking individual stocks is where the big moves are, in both directions. If you go that way, a few habits help: size each position so a 50% drop does not hurt you badly, know the date of the next catalyst before you buy, and read what the company actually reported rather than the headline.

Absci was trading near $2.50 in March 2026. Its company page showed three things at once. The cash had grown from $112 million to $127 million, with low dilution risk. Four hedge funds held the stock, led by Redmile, and together they had added almost three million shares. And directors had kept buying their own stock through the fall and winter. By July 7 the stock closed at $11.33.

That does not mean every stock with those checks goes up. It means the checks pointed at a company that could survive long enough for good news to matter.

The video below walks through the same checks live on Absci, Erasca and Amylyx.

• Buying the day after a big jump. By then the easy part of the move is often over.
• Ignoring the cash. A great drug in a company with eight months of money often comes with a share sale attached.
• Holding through a binary event with too much money. An FDA decision or a Phase 3 readout can cut a stock in half in one day.
• Confusing approval with profit. Approved drugs still have to sell. Some stocks fall right after an approval because the good news was already in the price.